Simplifying Deep Antibody Mining for Maximum Impact

In this webinar, learn how OmniAb is transforming antibody discovery by combining high-throughput functional screening with Genedata Biologics to streamline data integration, improve decision-making, and transform therapeutic development. 

Bob Chen, Vice President, Discovery Systems at OmniAb, will present how the company’s proprietary xPloration^® platform accelerates antibody discovery by enabling the rapid evaluation of millions of candidates and identifying thousands of promising hits within minutes. By integrating with Genedata Biologics — serving as the central bioregistration and data management hub — scientists can effortlessly link assay data such as ELISA, flow cytometry, and SPR with corresponding sequence information. This centralized data framework ensures data consistency, enhances traceability, and delivers actionable insights that drive efficiency and prevision across the entire discovery workflow. 

Learn how OmniAb uses Genedata to: 

• Centralize and structure complex biological data for faster, more informed decision-making.
• Streamline antibody discovery workflows with seamless integration of experimental data.
• Enable transparent, traceable selection of antibody candidates based on functional and sequence data.
• Support deep repertoire mining through synergy between high-throughput screening, next-generation sequencing (NGS), and AI-driven analysis.
• Visualize and analyze antibody activity by sequence similarity to identify high-potential clones.
• Enhance reproducibility and scalability of discovery campaigns with a robust, low-maintenance platform.